Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



MannKind Rents Out a Drug Program

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

MannKind (Nasdaq: MNKD  ) announced today that it licensed its preclinical BTK (Bruton's tyrosine kinase) program to Tolero Pharmaceuticals but included a take-back option in the deal. MannKind has until 60 days after the conclusion of the first phase 1 trial to invoke the option, which would have MannKind paying Tolero unspecified milestones, royalties, and sublicensing fees.

XOMA (Nasdaq: XOMA  ) did something similar in its deal with Laboratoires Servier, where it retained the right to buy back the U.S. and Japan rights to XOMA 052 in diabetes and cardiovascular indications. It seems some small biotechs want to have their cake and eat it, too.

The payment for the first half of the deal -- the compounds going to Tolero -- was specified, but it's not very useful to MannKind's investors. The biotech is due $130 million for upfront and milestone payments linked to development, approval, and commercialization of the drugs in the program, but there were no details about how that might break down.

It's pretty standard for biotechs to not lay out exactly when they'll get milestone payments. About all you can hope for is that the company will separate development and regulatory milestones from sales milestones that are years away and harder to obtain. Endocyte (Nasdaq: ECYT  ) combined them in its recent licensing deal with Merck (NYSE: MRK  ) . Exelixis (Nasdaq: EXEL  ) separated them out in its deal with Merck but didn't bother to disclose the amount of the milestones tied to sales. No reason to tip off the competition, I guess.

But biotechs usually break out how much they're getting upfront; Endocyte and Exelixis both did. And that would seem to be doubly important for a company that had just $3.2 million in cash and equivalents at the end of the year. MannKind raised about $80 million in February, so it's not in dire straits, but cash is still a big part of the story here. In the fourth quarter, MannKind burned through $20 million, and that'll increase as it completes enrollment in the additional trials the FDA wants before approving its inhaled insulin treatment Afrezza.

My guess is the upfront payment is fairly small, which is why MannKind didn't bother disclosing it. Still, superficially the deal looks like a good move to get the program off the expense sheet -- perhaps temporarily -- while it focuses on Afrezza, which has the biggest near-term potential. It just would be nice to have a bit more information to evaluate the deal.

Looking for more high-tech stock ideas? Check out the Fool's free report, "3 Hidden Winners of the iPhone, iPad, and Android Revolution," where you'll find three companies quietly cashing in on the booming smartphone and tablet PC markets. Get your free copy.

Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Exelixis. Motley Fool newsletter services have recommended buying shares of Exelixis. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1875324, ~/Articles/ArticleHandler.aspx, 10/28/2016 12:44:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 3 hours ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 4:00 PM
MNKD $0.49 Down -0.02 -3.79%
MannKind CAPS Rating: **
ECYT $2.86 Down -0.01 -0.35%
Endocyte CAPS Rating: ****
EXEL $10.92 Down -0.26 -2.33%
Exelixis CAPS Rating: ****
MRK $61.29 Up +0.42 +0.69%
Merck and Co. CAPS Rating: ****
XOMA $5.48 Up +0.02 +0.37%
XOMA CAPS Rating: **